MCID: DMY001
MIFTS: 43

Demyelinating Polyneuropathy

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Demyelinating Polyneuropathy

MalaCards integrated aliases for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy 12 15
Peripheral Demyelinating Neuropathy 12 71
Demyelinating Peripheral Neuropathy 6

Classifications:



External Ids:

Disease Ontology 12 DOID:5214
NCIt 49 C27062
SNOMED-CT 67 23414001
UMLS 71 C0270922

Summaries for Demyelinating Polyneuropathy

MalaCards based summary : Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to guillain-barre syndrome and multifocal motor neuropathy. An important gene associated with Demyelinating Polyneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and Spinal Cord Injury. The drugs Immunoglobulin G and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Subacute Inflammatory Demyelinating Polyneuropathy Acute and Subacute Inflammatory Demyelinating Polyneuropathy
Chronic Acquired Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)
# Related Disease Score Top Affiliating Genes
1 guillain-barre syndrome 33.1 PMP22 NFASC MAG HP ALB
2 multifocal motor neuropathy 31.6 FCGR2B CNTN2
3 polyradiculoneuropathy 31.3 PMP22 NFASC MAG CNTN1 ALB
4 sensory peripheral neuropathy 31.1 PMP22 NGF MAG ALB
5 mononeuropathy 31.0 PMP22 NGF MAG
6 mononeuritis multiplex 31.0 PMP22 MAG
7 chronic polyneuropathy 30.9 PMP22 MAG FCGR2B
8 miller fisher syndrome 30.8 PMP22 NFASC MAG CNTN1
9 demyelinating disease 30.7 PMP22 NGF MMP9 MAG
10 diabetic neuropathy 30.7 PMP22 NGF GDNF
11 median neuropathy 30.6 TTR PMP22
12 autoimmune neuropathy 30.5 PMP22 NFASC MAG FCGR2B CNTN1
13 chronic graft versus host disease 30.5 TNFSF13B ALB
14 neuritis 30.4 PMP22 MMP9 MAG GDNF
15 charcot-marie-tooth disease 30.3 TTR PMP22 NGF NFASC MAG GDNF
16 autoimmune peripheral neuropathy 30.3 MAG AIRE
17 optic nerve disease 30.3 NGF MAG ALB AIF1
18 autonomic neuropathy 30.3 TTR NGF ALB
19 polyneuropathy 30.2 TTR PMP22 NGF NFASC MAG IFNA2
20 neuromuscular disease 30.2 PMP22 MAG GDNF ALB
21 peripheral nervous system disease 30.2 TTR PMP22 NGF NFASC MAG GDNF
22 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 30.0 TTR IFNA2 HP ALB
23 thrombocytopenic purpura, autoimmune 30.0 IFNA2 FCGR2B CD52
24 corneal disease 30.0 NGF MMP9 ALB
25 metachromatic leukodystrophy 29.9 MAG GDNF ALB
26 hydrocephalus 29.9 TTR PTGDS NGF GDNF
27 central nervous system disease 29.8 TTR NGF MMP9 ALB
28 meningitis 29.7 PTGDS MMP9 GDNF ALB
29 meningoencephalitis 29.7 NGF GDNF CLDN5 ALB
30 thrombocytopenia 29.7 TNFSF13B MMP9 IFNA2 HP FCGR2B ALB
31 malaria 29.4 TTR TNFSF13B MMP9 HP FCGR2B ALB
32 multiple sclerosis 28.8 TNFSF13B PTGDS NGF MMP9 MAG CD52
33 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 12.9
34 chronic acquired demyelinating polyneuropathy 12.5
35 subacute inflammatory demyelinating polyneuropathy 12.5
36 chronic inflammatory demyelinating polyradiculoneuropathy 12.5
37 acute and subacute inflammatory demyelinating polyneuropathy 12.4
38 guillain-barre syndrome, familial 12.3
39 lewis-sumner syndrome 11.7
40 neuropathy, hereditary, with liability to pressure palsies 11.6
41 charcot-marie-tooth disease, axonal, type 2e 11.5
42 neurodevelopmental disorder with central and peripheral motor dysfunction 11.4
43 mannosidosis, beta a, lysosomal 11.3
44 canomad syndrome 11.3
45 charcot-marie-tooth disease, axonal, type 2a1 11.3
46 charcot-marie-tooth disease and deafness 11.3
47 charcot-marie-tooth disease, type 4a 11.3
48 marinesco-sjogren syndrome 11.3
49 charcot-marie-tooth disease, x-linked dominant, 6 11.3
50 charcot-marie-tooth disease, x-linked dominant, 1 11.3

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:



Diseases related to Demyelinating Polyneuropathy

Symptoms & Phenotypes for Demyelinating Polyneuropathy

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 AIRE CNTN1 CNTN2 FCGR2B GAS6 GDNF
2 homeostasis/metabolism MP:0005376 10.13 AIF1 AIRE ALB FCGR2B GAS6 HP
3 cardiovascular system MP:0005385 10.1 AIF1 ALB CLDN5 FCGR2B GAS6 GDNF
4 immune system MP:0005387 10 AIF1 AIRE ALB FCGR2B GAS6 GDNF
5 mortality/aging MP:0010768 9.97 AIRE ALB CLDN5 CNTN1 FCGR2B GAS6
6 digestive/alimentary MP:0005381 9.91 AIRE ALB CNTN1 FCGR2B GDNF MMP9
7 nervous system MP:0003631 9.77 AIF1 AIRE CLDN5 CNTN1 CNTN2 FCGR2B
8 renal/urinary system MP:0005367 9.17 ALB FCGR2B GAS6 GDNF HP MMP9

Drugs & Therapeutics for Demyelinating Polyneuropathy

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulin G Phase 4
2
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
3
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
4 Pharmaceutical Solutions Phase 3
5
rituximab Approved Phase 2 174722-31-7 10201696
6
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
7
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
8
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
9
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
10
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
11
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
12 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
13
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
15
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
16 Micronutrients Phase 2
17 Trace Elements Phase 2
18 Alpha-lipoic Acid Phase 2
19 Vitamins Phase 2
20 Vitamin B Complex Phase 2
21 Antioxidants Phase 2
22 Thioctic Acid Phase 2
23 Folate Phase 2
24 Nutrients Phase 2
25 Vitamin B9 Phase 2
26 Hormone Antagonists Phase 1, Phase 2
27 Hormones Phase 1, Phase 2
28 Antineoplastic Agents, Hormonal Phase 1, Phase 2
29 glucocorticoids Phase 1, Phase 2
30 Anti-Inflammatory Agents Phase 1, Phase 2
31 Protective Agents Phase 1, Phase 2
32 Autoantibodies Phase 2
33 Antineoplastic Agents, Immunological Phase 2
34 polysaccharide-K Phase 1, Phase 2
35 Gastrointestinal Agents Phase 1, Phase 2
36 Methylprednisolone Acetate Phase 1, Phase 2
37 Antibodies, Monoclonal Phase 1, Phase 2
38 Neuroprotective Agents Phase 1, Phase 2
39 Antiemetics Phase 1, Phase 2
40 Thymoglobulin Phase 1, Phase 2
41 Antilymphocyte Serum Phase 1, Phase 2
42 Antibodies Phase 2
43 Immunoglobulins, Intravenous Phase 2
44 Rho(D) Immune Globulin Phase 2
45 gamma-Globulins Phase 2
46 Immunoglobulins Phase 2
47 Immunologic Factors Phase 2
48 Fibrinolytic Agents Phase 2
49 Tissue Plasminogen Activator Phase 2
50 Plasminogen Phase 2

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Active, not recruiting NCT03684018 Phase 4
3 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
4 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
5 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
6 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
7 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
8 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
9 An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02293460 Phase 3 I10E
10 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
11 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
12 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
13 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
14 International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302" Terminated NCT02317562 Phase 3 I10E
15 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
16 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
17 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
18 Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety. Completed NCT02637700 Phase 2 Intravenous Immunoglobulin;Placebo
19 Safety, Tolerability, and Efficacy of Rituximab in Patients With Anti-Glycoconjugate Antibody-Mediated Demyelinating Neuropathy: A Double-Blind Placebo-Controlled Randomized Trial Completed NCT00050245 Phase 2 Rituximab
20 A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04281472 Phase 2
21 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Active, not recruiting NCT03864185 Phase 2
22 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
23 Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
24 Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT04280718 Phase 2
25 Intravenous Immunoglobulin (IVIG) in the Treatment of Autoimmune Small Fiber Neuropathy Due to TS-HDS and FGFR-3 Antibodies: a Double Blinded Placebo-controlled Phase II Trial Not yet recruiting NCT04153422 Phase 2 Gammagard IVIG;Placebo
26 Thrombolysis in Ischemic Spinal Cord Stroke Terminated NCT02242084 Phase 2 Intravenuse Alteplase
27 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
28 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
29 Electromyography Evaluation of the Stabilizing Muscles of the Scapula and Tibial Anterior Muscle, After an Intervention Program by Proprioceptive Neuromuscular Facilitation in Muscle Force Irradiation. Unknown status NCT02255708 Phase 1
30 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
31 A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT02465359 Immune Globulin Subcutaneous (Human)
32 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
33 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
34 A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®) Completed NCT03779828
35 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
36 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins
37 Observational Study of the Prevalence of Some Genetic Mutations in Patients With Neuropathy Associated With Anti-Myelin-associated Glycoprotein (MAG) Antibodies. Completed NCT03268161
38 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
39 A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives Recruiting NCT01931644
40 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Recruiting NCT03008733
41 Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER) Active, not recruiting NCT02414490 Intravenous Immunoglobulin
42 A Registered Cohort Study of Immune-Mediated Neuropathies Not yet recruiting NCT04292834
43 Study of Gait and Posture in Subacute Acquired Neuropathies and in Hereditary Neuropathies Not yet recruiting NCT04154540
44 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT03772717 Standard of Care
45 Investigation of Plastic Changes in the CNS Associated With Peripheral Neuropathy Not yet recruiting NCT03805893

Search NIH Clinical Center for Demyelinating Polyneuropathy

Genetic Tests for Demyelinating Polyneuropathy

Anatomical Context for Demyelinating Polyneuropathy

MalaCards organs/tissues related to Demyelinating Polyneuropathy:

40
T Cells, Spinal Cord, Testes, Brain, Skin, Bone, B Cells

Publications for Demyelinating Polyneuropathy

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 2364)
# Title Authors PMID Year
1
Abnormal motor unit firing rates in chronic inflammatory demyelinating polyneuropathy. 61
32402831 2020
2
Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment. 61
32364302 2020
3
Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies. 61
32012299 2020
4
Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155. 61
32563125 2020
5
The Misdiagnosis of CIDP: A Review. 61
32219701 2020
6
Neurological complications associated with influenza in season 2017/18 in Austria- a retrospective single center study. 61
32302952 2020
7
High-Resolution Nerve Ultrasound to Assess Nerve Echogenicity, Fascicular Count, and Cross-Sectional Area Using Semiautomated Analysis. 61
32521091 2020
8
What Can Mimic Multiple Sclerosis? 61
32448485 2020
9
Genotype-phenotype correlation in a novel ABHD12 mutation underlying PHARC syndrome. 61
32077159 2020
10
A review of pathophysiology and neuropsychiatric manifestations of COVID-19. 61
32494854 2020
11
Recurrent Demyelinating Episodes as Sole Manifestation of Inherited CD59 Deficiency. 61
31752029 2020
12
Acute Demyelinating Polyneuropathy in a Child with Dengue Shock Syndrome. 61
32542487 2020
13
BAG3 Myopathy Presenting With Prominent Neuropathic Phenotype and No Cardiac or Respiratory Involvement: A Case Report and Literature Review. 61
32453099 2020
14
Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature. 61
32388880 2020
15
Electrodiagnostic accuracy in polyneuropathies: supervised learning algorithms as a tool for practitioners. 61
32518996 2020
16
Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome. 61
32245766 2020
17
Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. 61
32410146 2020
18
Acute inflammatory demyelinating polyneuropathy following interruption of antiretroviral treatment and HIV rebound. 61
31998944 2020
19
High Levels of Il-19 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. 61
32472395 2020
20
Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy. 61
32217467 2020
21
Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy. 61
32388856 2020
22
Rituximab for chronic inflammatory demyelinating polyneuropathy-A potential therapeutic option. 61
32232860 2020
23
Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. 61
31922613 2020
24
Assessment of IL-38 Levels in Patients with Acquired Immune-Mediated Polyneuropathies. 61
32367504 2020
25
Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. 61
32404895 2020
26
Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells. 61
32375895 2020
27
Clinical features of Guillain-Barré syndrome patients with elevated serum creatine kinase levels. 61
32460711 2020
28
Comparison of the Clinical Outcomes of Guillain Barre Syndrome Based on Electrophysiological Subtypes in Pakistani Children. 61
32537271 2020
29
A novel frameshift mutation in SOX10 causes Waardenburg syndrome with peripheral demyelinating neuropathy, visual impairment and the absence of Hirschsprung disease. 61
32150337 2020
30
A case of combined central and peripheral demyelination in Zambia. 61
31958671 2020
31
Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. 61
32006783 2020
32
[Pitfalls for Diagnosis of Polyneuropathy by Nerve Conduction Study]. 61
32284466 2020
33
Use of Magnetic Resonance Neurography for Evaluating the Distribution and Patterns of Chronic Inflammatory Demyelinating Polyneuropathy. 61
32193896 2020
34
Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy. 61
32279669 2020
35
Epidemiology of chronic inflammatory demyelinating polyneuropathy in the South-Eastern area of Santiago, Chile. 61
32067826 2020
36
Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates. 61
31769579 2020
37
Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care: A Review of Clinical and Laboratory Assessment Measures. 61
32338716 2020
38
Diagnosing peripheral neuropathy in South-East Asia: A focus on diabetic neuropathy. 61
32268012 2020
39
Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. 61
31959710 2020
40
Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. 61
31571349 2020
41
Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. 61
31766959 2020
42
Co-occurrence of Merkel Cell Carcinoma and Chronic Inflammatory Demyelinating Polyneuropathy. 61
32159728 2020
43
A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. 61
31793666 2020
44
Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. 61
31941581 2020
45
Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing. 61
32411930 2020
46
Treatment-related fluctuations in subacute inflammatory demyelinating polyneuropathy. 61
32055719 2020
47
Treatment of painful polyneuropathies of diabetic and other origins with 10 kHz SCS: a case series. 61
32073352 2020
48
Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology. 61
31734909 2020
49
Axonal variants of Guillain-Barré syndrome: an update. 61
32140865 2020
50
Hyper-reflexia in Guillain-Barré syndrome: systematic review. 61
31937584 2020

Variations for Demyelinating Polyneuropathy

ClinVar genetic disease variations for Demyelinating Polyneuropathy:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KIF5A NM_004984.4(KIF5A):c.2005G>A (p.Ala669Thr)SNV Uncertain significance 816537 12:57969522-57969522 12:57575739-57575739

Expression for Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Demyelinating Polyneuropathy.

Pathways for Demyelinating Polyneuropathy

Pathways related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.52 NFASC MAG CNTN2 CNTN1 CLDN5
2 11.1 TNFSF13B MMP9 MAG GDNF AIF1

GO Terms for Demyelinating Polyneuropathy

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TTR TNFSF13B PTGDS NGF MMP9 IFNA2
2 extracellular space GO:0005615 9.65 TTR TNFSF13B PTGDS NGF MMP9 IFNA2
3 node of Ranvier GO:0033268 9.4 NFASC CNTN2
4 Schmidt-Lanterman incisure GO:0043220 9.37 MAG CLDN5
5 compact myelin GO:0043218 9.32 PMP22 MAG
6 anchored component of postsynaptic membrane GO:0099025 9.26 CNTN2 CNTN1
7 paranode region of axon GO:0033270 8.8 NFASC MAG CLDN5

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelination GO:0042552 9.5 PMP22 NFASC CLDN5
2 cerebellum development GO:0021549 9.43 FCGR2B CNTN1 AIF1
3 negative regulation of apoptotic process GO:0043066 9.43 NGF MMP9 GDNF GAS6 ALB AIF1
4 central nervous system myelination GO:0022010 9.37 MAG CNTN2
5 protein localization to juxtaparanode region of axon GO:0071205 9.16 NFASC CNTN2
6 peripheral nervous system development GO:0007422 8.92 PMP22 NGF NFASC GDNF

Molecular functions related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.02 TNFSF13B NGF MAG GDNF GAS6

Sources for Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....